|View printer-friendly version|
Portola Pharmaceuticals to Announce Second Quarter 2013 Financial Results and Host Conference Call on Thursday, August 15, 2013
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug. 7, 2013--
Conference Call Details
To access the live conference call on
To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company’s website at http://investors.portola.com. Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.
Portola is a biopharmaceutical company focused on the development and commercialization of novel therapeutics in the areas of thrombosis (blood clots), other hematologic (blood) disorders and inflammation for patients who currently have limited or no approved treatment options.
Portola’s lead compound, betrixaban, is an investigational, novel, oral once-daily inhibitor of Factor Xa in Phase 3 development for extended-duration prophylaxis (preventive treatment) of a form of thrombosis known as venous thromboembolism (VTE) in acute medically ill patients.Currently, there is no anticoagulant approved for extended-duration VTE prophylaxis in this population.
Portola’s second lead development candidate, andexanet alfa (proposed International Nonproprietary Name), is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or require emergency surgery. Portola has entered into collaboration agreements with
Portola’s third product candidate, PRT2070, is an orally available kinase inhibitor being developed for hematologic cancers and inflammatory disorders. PRT2070 inhibits spleen tyrosine kinase (Syk) and janus kinases (JAK), enzymes that regulate important signaling pathways.Portola plans to file an Investigational New Drug (IND) application and initiate a Phase 1/2 clinical study of PRT2070 in 2013 in patients with B-cell hematologic cancers who have failed or relapsed on existing marketed therapies or products in development, including patients with identified mutations. Portola’s fourth program, PRT2607 and other highly selective Syk inhibitors, is partnered with